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Abstract: This article aims to highlight current trends in the pharmacologic management of 
obsessive–compulsive disorder (OCD). A systematic search of the electronic database MEDLINE 
was conducted. The first case report of clomipramine efficacy in the management OCD more 
than 40 years ago gave new hope for the treatment of this debilitating disorder. Selective 
serotonin reuptake inhibitors (SSRIs) proved to have a similar efficacy profile compared with 
clomipramine but had a superior tolerability profile. While many patients with OCD respond 
to SSRIs or clomipramine, the treatment of those with refractory OCD remains challenging. 
  Different augmentation agents in treatment-resistant OCD have been explored, with antipsychotic 
agents having the largest supporting evidence base. Nevertheless, new pharmacologic treatment 
options are required and are under investigation.
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Introduction
Obsessive–compulsive disorder (OCD) is a chronic condition characterized by 
  obsessions or compulsions that cause distress or interfere with functioning. Obsessions 
are repetitive thoughts or urges that may lead to distress or anxiety. Compulsions are 
repetitive behaviors or thoughts that are performed according to rigorous rules, or 
in response to obsessions.1 OCD is associated with significant suffering, leads to a 
great deal of morbidity, and is associated with major economic costs. Many aspects 
of quality of life are negatively impacted by OCD, and there is an association between 
increased OCD severity and worse quality of life.2 A number of clinical trials have 
been conducted on OCD and several others are ongoing, so updated reviews of this 
work are useful for clinicians. The aim of this article is to highlight current trends 
in the pharmacologic management of OCD. We conducted a systematic search of 
the electronic database MEDLINE using the MeSH term “obsessive–compulsive 
disorder” for all available articles published up to and including 2009. We used the 
additional search terms “drug treatment” and “pharmacotherapy” to refine the search. 
We further limited the search using specific drug names, selecting English language 
publications only, and choosing only randomized or controlled trials, systematic 
reviews, and meta-analyses.
Epidemiology
The lifetime prevalence estimate of OCD is 1%–3%, with older adolescents particularly 
prone to developing the disorder, and the incidence declining in older age groups.3–5 Neuropsychiatric Disease and Treatment 2010:6 234
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Males comprise the majority of very early onset cases, while 
females comprise the majority of new cases after the age of 
10 years.4 In a five-decade prospective study of the course of 
OCD, only 20% of patients had complete recovery, although 
most had some improvement in both clinical symptoms 
and social functioning.6 Early onset of OCD is associated 
with lower rates of recovery.4,6 A recent community study 
indicated that more than 90% of patients with a lifetime 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) OCD diagnosis met criteria for another 
lifetime DSM-IV disorder, and the most common comorbid 
conditions were anxiety disorders (75.8%), followed by mood 
disorders (63.3%), impulse-control disorders (55.9%), and 
substance abuse disorders (38.6%).4 In clinic patients, anxiety 
disorder is also the most common comorbid condition (76%), 
followed by major depressive disorder (33%).7
Etiology
Functional imaging of the brain has allowed exploration of 
brain structure and function in OCD patients and has indi-
cated hyperactivity in the orbitofrontal cortex, anterior cingu-
late cortex, and caudate nucleus of patients with the disorder.8 
These findings suggest that abnormalities in the corticobasal 
ganglia-thalamo-cortical loops involving the orbitofrontal 
cortex and anterior cingulate cortex play a role in the patho-
genesis of OCD.9 The corticobasal ganglia-thalamo-cortical 
network is innervated by a variety of neurotransmitter path-
ways, and particular interest has been paid to the dopamine 
and serotonin (5-HT) neurotransmitter systems in OCD.
The exact etiology of OCD remains uncertain but 
  systematic family and twin studies have demonstrated the 
moderate heritability of OCD.10 A range of association 
  studies to identify genetic components possibly involved in 
the etiology of OCD has been undertaken.11 Disappointingly, 
however, gene association studies have often failed to 
  replicate one another. For example, there are inconsistent 
findings with respect to polymorphisms in the genes 
  responsible for the serotonin transporter, dopamine 
  transporter, and serotonin and dopamine receptor subtypes 
in OCD.11–13 It is possible that multiple genes, each with 
small effects, contribute to OCD.
Environmental factors, especially adverse perinatal 
  experiences, may be associated with the development of 
OCD. Compared with controls, mothers of children with 
OCD had significantly higher rates of illness requiring 
  medical care during pregnancy, and had more birth difficulties 
(induced labor, forceps delivery, cord prolapse, or prolonged 
labor).14 Group A β-hemolytic streptococcal throat infections 
have been associated with childhood onset of OCD, and 
this has been termed PANDAS (pediatric autoimmune 
  neuropsychiatric disorders associated with streptococcal 
infection).15 It has been suggested that PANDAS may be 
triggered by an autoimmune response whereby reactive 
lymphocytes and antibodies against Group A β-hemolytic 
Streptococcus cross the blood–brain barrier and cross-react 
with neural cells to produce dysfunction in the central 
  nervous system, specifically the basal ganglia. Further work 
is needed to confirm this hypothesis.15
A range of animal models of OCD has been developed.16 
Such work aims ultimately to develop new treatments 
for OCD based on a better understanding of the basic 
  mechanisms that contribute to the disorder. On the one 
hand, there have been significant advances in understanding 
such mechanisms and we arguably have a more rigorous 
understanding of the neuroanatomy and neurochemistry of 
this relatively homogeneous disorder than we have of many 
other more heterogeneous psychiatric disorders. At the same 
time, much remains to be understood, and work on animal 
models of OCD has not yet translated into novel findings in 
clinical studies.
History of pharmacotherapy  
in OCD
The first case report indicating that the tricyclic antidepressant, 
clomipramine, might have some benefit in patients with 
OCD was published more than 40 years ago.17 Since then, 
  clomipramine has been studied thoroughly and was the first 
drug approved by the US Food and Drug Administration (FDA) 
for the treatment of OCD. Clomipramine acts by inhibiting 
the reuptake of norepinephrine and serotonin, but serotonin 
  inhibition is more pronounced. The selectivity of clomipramine 
for serotonin led to the hypothesis that a serotonin deficit 
is responsible for the symptoms of OCD.18 This hypothesis 
also gave impetus to the study of selective serotonin reuptake 
  inhibitors (SSRIs) in OCD, in the hope that those agents would 
be more efficacious and better tolerated.19
Best treatment: SSRIs  
or clomipramine?
The response of OCD patients to pharmacologic intervention 
can be measured using a range of scales. The Yale–Brown 
Obsessive Compulsive Scale (YBOCS) score is the most 
widely used clinician-rated severity scale in OCD research.20 
The score range of the YBOCS is 0–40, with higher scores 
representing more severe symptoms. A response to treatment 
is usually, but not always, defined as a 25% or more reduction Neuropsychiatric Disease and Treatment 2010:6 235
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in YBOCS score after treatment initiation.21 Another 
  measure used to determine efficacy in OCD research is the 
Clinical Global Impression scale (CGI), which rates patients 
  according to severity of illness, global improvement, and 
efficacy of treatment.22
Using the symptom severity scales, data can be meta-
  analyzed to quantify the efficacy of different agents in the 
pharmacotherapy of OCD. Table 1 summarizes published 
meta-analyses of short-term OCD treatment studies. Early 
meta-analyses suggested that both SSRIs and clomipramine 
were more effective than placebo. Of note is that when the 
data for the SSRIs were compared with clomipramine, clo-
mipramine generally had greater effect sizes. However, head-
to-head studies have found similar efficacy for clomipramine 
and SSRIs. This may partly be explained by the fact that clo-
mipramine studies were typically conducted earlier; patients 
were treatment-naive (and so perhaps more responsive), and 
placebo response was low. In contrast, the SSRI studies may 
have included patients who had previously failed to respond 
to other agents, and placebo responses were higher.
As discussed above, individual studies comparing SSRIs 
with clomipramine demonstrate very little difference in effi-
cacy. In a small study, fluoxetine (40 mg daily) showed similar 
efficacy compared with clomipramine (150 mg daily), and 
both treatments were well tolerated.23 Comparisons between 
fluvoxamine and clomipramine demonstrated equal efficacy, 
although again both studies were small (clomipramine 
100–250 mg versus fluvoxamine 100–250 mg, and clomip-
ramine 150–300 mg versus fluvoxamine 150–300 mg, with 
both drugs administered daily).24,25 In an adequately powered 
comparison of sertraline and clomipramine, no significant 
difference in efficacy was found.26
Table 1 Summary of meta-analyses of clomipramine and selective serotonin reuptake inhibitors in OCD
Study n Design (number of trials) Duration Effect on OCD
Greist et al75 1520 PL-controlled (7)  
[CMI, FLX, FLV, SER]
10–13 weeks CMI and SSRIs  PL  
CMI  SSRIs  
No significant difference  
in drop-outs because 
of adverse effects
Piccinelli et al76 1809 PL-controlled (26) 
[CMI, FLX, FLV, SER, TCA]
5–36 weeks CMI and SSRIs  PL  
CMI  SSRIs
Stein et al77 1039 PL-controlled (12) 
[FLX, FLV, SER, TRZ, CMI]  
Head-to-head (10) 
Open trial (6)
6–13 weeks CMI and SSRIs  PL  
CMI = SER  FLX
Abramowitz78 20 studies with a range  
of 10–519 participants  
in each study
PL-controlled (5)  
[FLX, FLV, SER, CMI]  
Head-to-head (4)
4–13 weeks CMI and SSRIs  PL  
CMI  FLV  FLX  SER 
Adverse effects  
correlated with effect size
Kobak et al79 4641 PL-controlled (5)  
[FLX, FLV, SER, CMI, PAR]  
Head-to-head (7)
Not reported CMI and SSRIs  PL  
CMI = FLV = FLX  
other SSRIs  
No difference in drop-out 
rates
Ackerman et al80 1876 PL-controlled (18) 
[CMI, FLX, FLV, SER, PAR]  
Head-to-head (8)
8–13 weeks CMI and SSRIs  PL  
CMI = FLV = FLX = PAR
Soomro21 3097 PL-controlled (17)  
[FLX, FLV, SER, PAR, CIT]
6–13 weeks Overall RR 1.84  
(95% CI 1.56–2.17)  
Citalopram RR 1.58  
(95% CI 1.20–2.08)  
Fluoxetine RR 2.41  
(95% CI 1.58–4.56)  
Paroxetine RR 1.74  
(95% CI 1.28–2.36)  
Sertraline RR 1.54  
(95% CI 1.20–1.99)  
NNT 6–12
Abbreviations: CMI, clomipramine, FLX, fluoxetine; FLV, fluvoxamine; SER, sertraline; TRZ, trazodone; TCA, tricyclic antidepressants; PAR, paroxetine; CIT, citalopram, PL, 
placebo; SSRI, selective serotonin reuptake inhibitor; RR, relative risk; NNT, number-needed-to-treat, OCD, obsessive-compulsive disorder.Neuropsychiatric Disease and Treatment 2010:6 236
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A recent Cochrane review compared the SSRIs in terms 
of their efficacy and tolerability in OCD.21 The SSRIs of 
interest were fluoxetine, fluvoxamine, sertraline, paroxetine, 
and citalopram. The SSRIs as a group were shown to be 
more effective for treating OCD symptoms compared with 
placebo, and individually all drugs showed effect sizes of 
reasonable magnitude. Narrow confidence intervals (CIs) 
were reported for citalopram, fluvoxamine, paroxetine, 
and sertraline, and with slightly wider CIs for fluoxetine 
  studies. The overall relative risk (RR) for response rate 
across all five SSRI studies was 1.84 (95% CI: 1.56–2.17). 
The RR for response rate in the citalopram group was 
1.58 (95% CI: 1.20–2.08), fluoxetine 2.41 (95% CI: 1.58–4.56), 
paroxetine 1.74 (95% CI: 1.28–2.36), and sertraline 1.54 
(95% CI: 1.20–1.99). Citalopram, paroxetine, and sertraline 
showed similar effect sizes (in terms of improvement in 
Y-BOCS scores) of 1.54–1.74, while fluvoxamine and 
fluoxetine showed larger effect sizes. However, lower limits 
of the CIs of effect sizes of all five drugs individually were 
comparable and the difference between the individual drugs 
was not statistically significant. The numbers needed to 
treat were calculated assuming that a response rate without 
treatment would be between 10% and 20%. Should 10% 
of patients be expected to recover without treatment, 12 
patients would need to be treated with an SSRI to achieve 
improvement for one additional patient and should 20% of 
patients be expected to recover without treatment, six patients 
would need to be treated to achieve improvements for one 
  additional patient.
Similarly, a systematic review of long-term medication stud-
ies in OCD shows that agents that are effective in short-term 
treatment are typically effective during long-term treatment.17 For 
example, studies of clomipramine, escitalopram, fluoxetine, and 
sertraline have found that treatment effect is maintained beyond 
12 weeks. Relapse prevention trials have also tended to show 
significant advantages for patients remaining on medication.
Thus, the evidence does not support superior efficacy 
of clomipramine over the SSRIs or of one SSRI over others 
in the same drug class for the treatment of OCD. However, 
the drugs have differences in tolerability and the potential 
to cause interactions.
Tolerability of serotonin reuptake 
inhibitors and clomipramine
SSRIs increase synaptic availability of serotonin, and a 
number of postsynaptic 5-HT receptor types, including 
those for 5-HT3, are stimulated. Stimulation of such recep-
tors is suspected to be responsible for some of the adverse 
effects of SSRIs. Although reported adverse effect data were 
limited in the Cochrane review,21 the overall and individual 
adverse effects for the different SSRIs were always worse 
than for placebo, and in the majority of cases the difference 
was statistically significant. Nausea, headache, and insom-
nia were consistently reported amongst the most common 
adverse effects in trials of each of the drugs. SSRIs were 
particularly prone to cause sexual side effects and the rela-
tive risk ranged from 5.74 to 18.64 for the individual drugs 
compared with placebo. The reviewers concluded that the 
modest OCD symptom improvement achieved by utilizing 
SSRIs should be weighed against the adverse effects, par-
ticularly those that impact on quality of life, such as sexual 
adverse effects.
Epileptic seizures have been reported during treatment 
with almost all antidepressants, including clomipramine and 
the SSRIs. The bulk of evidence suggests that clomipramine 
has a relatively high seizure risk, while SSRIs have a lower 
seizure risk. The seizure risk seems to be dose-related.27
Both clomipramine and the SSRIs are associated with 
weight gain in the long-term (more than two years) treatment 
of patients with OCD.28 Clomipramine appears to have the 
greatest potential to induce weight gain, and sertraline and 
fluoxetine the least. Weight gain seems to be more signifi-
cant for females. The small sample studied in OCD limits 
rigorous comparisons between SSRIs, but a meta-analysis of 
second-generation antidepressants for the treatment of major 
depressive disorder indicated that paroxetine might have the 
greatest propensity to cause weight gain.29
Clomipramine blockade of muscarinic, histaminergic, 
and adrenergic receptors decreases tolerability. Common 
adverse effects include blurred vision, xerostomia, urinary 
retention, constipation, orthostatic hypotension, and sedation. 
The major safety concern with the use of clomipramine is 
the drug’s ability to slow cardiac conduction, which may 
precipitate life-threatening arrhythmias in overdose. The 
increased toxicity in overdose might be due to modulation 
of ion channel function, particularly for potassium and 
sodium, within the myocardium. UK mortality data 
show that tricyclic antidepressants are associated with a 
  significantly higher number of accidental and intentional 
deaths than SSRIs.30 Clomipramine was responsible for 
11 deaths per million prescriptions, while SSRIs as a class 
were responsible for two deaths per million prescriptions, 
confirming that SSRIs are rarely fatal in overdose. When 
fatal, the SSRI was mostly taken in combination with other 
drugs, particularly tricyclic antidepressants. Very high 
doses of SSRIs (75 times the normal daily dose) may Neuropsychiatric Disease and Treatment 2010:6 237
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cause more serious adverse effects, including seizures and 
decreased consciousness.31
In head-to-head studies, clomipramine discontinuation 
rates were higher than those for SSRIs. When fluvoxamine 
was compared with clomipramine, fluvoxamine was better 
tolerated, with clomipramine having twice the amount of 
withdrawals owing to adverse effects.25 In an adequately 
powered comparison between sertraline and clomipramine, 
significantly more patients withdrew from the clomipramine 
group due to adverse effects.26
In summary, as with all pharmacologic interventions, 
both clomipramine and SSRIs cause adverse effects, but 
the evidence suggests that SSRIs have a more favorable 
  tolerability profile than clomipramine.
Interactions with cytochrome  
P450 isoenzymes
The metabolism of most antidepressants is highly dependent 
on the activity of hepatic cytochrome P450 (CYP450) 
enzymes. Some antidepressants are not only substrates for 
CYP450 metabolism, but are also inhibitors of the metabolic 
clearance of other drugs, sometimes producing clinically 
significant drug-drug interactions.32 Fluvoxamine is a 
potent inhibitor of CYP1A2 and CYP2C9, while fluoxetine 
and paroxetine potently inhibit CYP2D6. Citalopram and 
  escitalopram are weak inhibitors of CYP450 isoenzymes and 
are less likely than other second-generation antidepressants 
to interact with coadministered medications.33 Clomipramine 
significantly inhibits CYP2C19.34
Interactions with CYP450 isoenzymes should be kept in 
mind when combining antidepressant treatment with other 
drugs, especially when augmenting treatment-resistant OCD 
patients.
Optimal dose of treatment
There is evidence to suggest that OCD drug response is bet-
ter at higher doses.35 Paroxetine was shown to have a positive 
dose-response relationship, with higher doses of 40 mg 
and 60 mg daily showing a significant improvement compared 
with placebo.36 No significant difference was demonstrated 
between the 20 mg daily dose and placebo. Fluoxetine was 
evaluated in three fixed doses (20, 40, and 60 mg daily) and, 
although all doses were effective, the highest dose tended to 
give the greatest benefit. This finding did not reach statistical 
significance and adverse effects were dose-related.37 A dose-
finding study of escitalopram in nonresistant OCD suggested a 
dose-response effect with 20 mg daily which was numerically 
more robust than 10 mg daily on some secondary measures.38 
There were no significant adverse event differences between 
the two dosage groups.
Success with doses greater than those recommended in 
the summary of product characteristics has been shown in 
treatment-refractory patients. A multicenter, randomized, 
double-blind, nonplacebo trial was performed to evaluate 
the efficacy and safety of 12 additional weeks of high-dose 
sertraline (250–400 mg, mean 357 mg daily) in 30 OCD 
patients who had failed to respond to 16 weeks of standard-
dose sertraline treatment.39 High doses of sertraline resulted 
in significantly greater and more rapid improvement in 
OCD symptoms compared with the maximal labeled dose 
of sertraline (200 mg daily). Obsessive, but not compulsive 
symptoms, also responded faster to high-dose sertraline 
compared with sertraline 200 mg daily. The higher doses of 
sertraline were well tolerated and produced similar rates of 
adverse effects compared with 200 mg, although patients 
had higher rates of tremor and agitation at higher doses. 
Pampaloni et al described the frequency and outcome of 
off-label doses of SSRIs prescribed in treatment-refractory 
patients.40 Patients on high-dose treatment showed significant 
within-group improvements, although Y-BOCS scores for the 
high-dose group remained significantly higher than control 
patients treated for a matched period, suggesting enduring 
treatment resistance. No differences were found between 
the cases and controls with respect to the adverse effects, 
although the sample size was small and the findings limited 
by the retrospective study design.
Currently, expert consensus guidelines recommend 
  gradually increasing the SSRI dose to the maximum, and 
do not recommend doses above the limit specified in the 
  summary of product characteristics. Should patients not 
respond after an adequate medication trial, medication should 
be changed or augmented with another agent.41,42
Resistant obsessive–compulsive 
disorder
Despite the substantial clinical improvements provided by 
the pharmacologic treatment of OCD with clomipramine and 
SSRIs, it has been estimated that 40%–60% of patients do 
not respond completely.43 Various alternative strategies have 
been proposed for the treatment of resistant OCD.
Increased dose of serotonin  
reuptake inhibitor
As discussed above, SSRIs have been used beyond the 
  recommended maximum dose for patients who responded 
poorly to treatment and who tolerated supratherapeutic Neuropsychiatric Disease and Treatment 2010:6 238
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doses. An open-label, prospective, 16-week, high-dose 
escitalopram study demonstrated statistically significant 
improvement in Y-BOCS score compared with baseline 
in patients receiving high doses.44 Patients with resistant 
OCD received a mean dose of escitalopram 33.8 mg daily 
that was well tolerated with no treatment discontinuations. 
In a multicenter, double-blind trial, 66 nonresponders to 
16 weeks of sertraline 50–200 mg daily were randomized 
to sertraline 200 and 250–400 mg daily. The high-dose 
group demonstrated significantly greater improvement 
compared with the 200 mg daily group. None of the 
patients in the high dose group discontinued due to 
adverse effects.39
A retrospective folder review matched 192 patients 
receiving high-dose SSRIs (fluoxetine, citalopram, 
  fluvoxamine, paroxetine, sertraline, and escitalopram) with 
a matched number of cases receiving the standard-dose 
  treatment.40 Patients on the high-dose treatment showed sig-
nificant within-group improvements (mean Y-BOCS score 
25.35 at baseline versus 20.95 at endpoint), although endpoint 
scores for the high-dose group remained significantly higher 
than for the control patients for a matched period, suggesting 
enduring treatment resistance. Frequency of adverse effects 
did not significantly differ between the two groups, although 
this finding is limited by the retrospective design of the 
study.
Augmentation of SSRIs  
with antipsychotics
Evidence of the potential involvement of the dopamine 
system in OCD gave impetus to the study of whether 
  antipsychotics could augment SSRIs in the treatment of 
the disorder. Addition of haloperidol was found to be par-
ticularly efficacious in SSRI-refractory OCD patients with 
comorbid chronic tic disorders, such as Tourette’s disorder, 
although it was of little benefit in patients without tics.45
Risperidone is an atypical antipsychotic agent with potent 
dopaminergic and serotonergic antagonist activity.46 A ran-
domized, placebo-controlled augmentation trial of risperidone 
by McDougle demonstrated a 50% response rate, as defined 
by a 35% reduction in Y-BOCS score and “improved” or 
“much improved” CGI score, in patients receiving a six-week 
course of this agent. Risperidone was well tolerated with no 
treatment discontinuations. Erzegovesi investigated fluvox-
amine-refractory patients, and 5/10 patients randomized 
to risperidone augmentation versus 2/9 patients receiving 
placebo had a significant response.47 Risperidone was again 
well tolerated.
Results of placebo-controlled trials with another atypical 
antipsychotic, olanzapine, are conflicting. Shapira et al 
found no additional advantage of adding olanzapine in OCD 
patients refractory to fluoxetine, compared with extending 
the monotherapy trial,48 while Bystritsky concluded that 
adding olanzapine to SSRIs is potentially efficacious in the 
short-term treatment of patients with refractory OCD.49
A randomized, placebo-controlled trial of quetiapine 
  augmentation demonstrated significant improvement in 
the quetiapine arm, with 9/14 refractory patients showing 
significant improvement in the Y-BOCS score.50 A larger 
randomized, placebo-controlled trial in 40 patients with 
  treatment-resistant OCD demonstrated a significant 
  difference in Y-BOCS score between quetiapine and 
  placebo in favor of the antipsychotic. Eight patients in the 
quetiapine group compared with two in the placebo group 
had 35% decrease in Y-BOCS score after eight weeks’ 
treatment.51 While the antipsychotic was well tolerated, 
30% of patients had an increase in weight. Carey et al 
found no difference in patients augmented with placebo or 
quetiapine, but pointed out that their findings might reflect a 
shorter trial of an SSRI before quetiapine augmentation and 
lower dosages of quetiapine compared with other trials.52 
The largest quetiapine placebo-controlled trial (n = 66) to 
date concluded that quetiapine was significantly superior 
to placebo on Y-BOCS score and CGI scale score, but 
quetiapine augmentation was associated with more patients 
discontinuing treatment as a result of adverse events.53 
A meta-analysis of quetiapine studies suggests that this 
agent may be effective in the augmentation of SSRIs for 
the treatment of refractory OCD.54
Clozapine failed to show benefit when used as monotherapy 
for the treatment of OCD.5 A series of basic science studies 
on the molecular effects of coadministration of SSRIs and 
  atypical antipsychotics give support for the strategy of 
  augmenting SSRIs with atypicals in refractory patients.
Until recently, all studies of atypical antipsychotic 
  augmentation in OCD investigated only short-term response. 
A long-term follow-up of at least 1.5 years of patients 
  receiving atypical antipsychotic augmentation raised 
  concerns about the efficacy and metabolic effects of atypi-
cal antipsychotics.56 Compared with SSRI responders, total 
Y-BOCS scores in those who required atypical antipsychotic 
augmentation were initially higher, and they remained at 
higher levels than those of SSRI responders after one year of 
treatment. This illustrates the disease severity in patients with 
resistant OCD but also the difficulty in obtaining an adequate 
response in these patients. Patients who received atypical Neuropsychiatric Disease and Treatment 2010:6 239
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antipsychotic augmentation had significant increases in body 
mass index and fasting blood glucose, and demonstrated a 
trend towards increased cholesterol and triglycerides. Again, 
the advantages and disadvantages of pharmacotherapeutic 
intervention must be carefully weighed.
Other drugs
Administration of the second messenger, inositol, in a 
small open-label study failed to produce a significant 
  improvement in the majority of refractory patients.57 
  Opioids are µ-receptor agonists and in a placebo-controlled, 
double-blind study, oral morphine reduced the symptoms of 
OCD.58 The evidence for anticonvulsants in patients with 
refractory OCD is mainly confined to anecdotal reports and 
uncontrolled trials.59
Alternative mode of SSRI administration
In a randomized placebo-controlled trial (n = 54), intra-
venous administration of clomipramine demonstrated 
superiority over placebo on outcome measures in patients 
who remained refractory to oral administration of clomip-
ramine.60
Augmentation of SSRI treatment  
with other agents
A number of clinical trials of augmentation strategies have 
failed to show any benefit in treatment-resistant OCD. In a 
double-blind, placebo-controlled trial, augmentation with 
lithium in treatment-resistant patients on fluvoxamine 
showed no clinical improvement in reducing   obsessive-
compulsive symptoms.61 Buspirone added to fluvoxamine 
proved to be no better than placebo in reducing symptoms.62 
  Adjunctive desipramine also showed no significant 
  difference compared with placebo augmentation on OCD 
symptoms.63
A Cochrane review of the pharmacotherapy of 
  treatment-resistant anxiety disorder concluded that more 
than twice as many treatment-resistant OCD patients 
respond to pharmacotherapy augmentation with various 
drugs than to placebo (31.8% versus 13.6%). The number 
needed to treat was found to be a clinically acceptable 5.5 
and pharmacologic augmentation was tolerable insofar as 
there was no difference between medication and placebo 
dropout rate. Overall, superiority of a variety of drugs to 
placebo was demonstrated with a relative risk of nonre-
sponse of 3.16 (95% CI: 1.08–9.23). A substantial propor-
tion of the efficacy evidence was for augmentation with 
antipsychotic agents.64
Future therapeutic options
Data for the efficacy of combining pharmacotherapy 
with cognitive behavioral therapy at the start of treatment 
is inconclusive, although patients who are resistant 
to pharmacotherapy may benefit from the addition of 
  psychotherapy.65–67
New therapeutic options for OCD continue to be explored. 
D-cycloserine is an N-methyl-D-aspartic acid (NMDA) 
partial agonist, and NMDA receptor stimulation has been 
linked with amygdala neural plasticity and fear extinction 
effects.68,69 D-cycloserine has been administered before an 
exposure task in various anxiety disorders, in the hope that 
stimulation of the NMDA receptor might help extinguish 
fear. In a randomized, double-blind, placebo-controlled trial 
of 23 OCD patients, D-cycloserine plus cognitive behavioral 
therapy improved OCD symptoms significantly at mid-treat-
ment and depressive symptoms significantly post-treatment 
compared with placebo.68 In another randomized, double-
blind, placebo-controlled trial in 32 patients, D-cycloserine 
plus cognitive behavioral therapy decreased obsession-
related distress significantly compared with placebo, but 
after additional exposure sessions, the difference was not 
seen. Patient drop-out rate was significantly higher in the 
placebo group.70
Riluzole, a glutamate antagonist, may hold promise for 
treatment-refractory patients.71
Treatment with modalities other than pharmacotherapy 
or psychotherapy has also been explored in patients with 
resistant OCD. Deep brain stimulation involves delivering 
a current via an implanted electrode that is connected to 
a battery-powered impulse generator that is implanted 
beneath the skin in the subclavicular region. The therapeutic 
  mechanism of action is modulation of neuronal network 
activity using a pulse generator surgically placed in various 
regions, including the anterior internal capsule. Several clini-
cal trials assessing the efficacy of deep brain stimulation in 
patients with OCD have shown promising results.72
Transcranial magnetic stimulation is a noninvasive 
  technique that delivers magnetic pulses to the cortex by 
means of a hand-held stimulating coil applied directly to 
the head.73 There is currently no reliable evidence to sup-
port the use of transcranial magnetic stimulation to treat 
OCD.74
Conclusion
There have been significant advances in pharmacotherapy 
for OCD, but further work remains to be done. Extensive 
evidence exists to support the efficacy of clomipramine Neuropsychiatric Disease and Treatment 2010:6 240
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and the SSRIs in the treatment of OCD. Clomipramine and 
the SSRIs are equally effective at relieving obsessions and 
compulsions, but the superior safety and tolerability of SSRIs 
make them the treatment of choice. However, SSRIs are not 
devoid of adverse effects which may significantly impact on 
patient quality of life. Treatment-refractory OCD remains 
an important clinical issue; antipsychotic augmentation is 
recommended, but is effective and well tolerated in a pro-
portion of patients. There have been significant advances in 
uncovering the neurobiology of OCD, and ongoing work 
might ultimately be translated into novel approaches to the 
pharmacotherapy of OCD in the future.
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